Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

ITC reported for 6 months of 2023 by RAS

7/25/23 WTCM

Ozon launches its own logistics infrastructure in Armenia

7/25/23 OZON

Fesco may open a container terminal in the port of the Astrakhan region

7/25/23 FESH

Softline has confirmed the exchange of its shares for Noventiq receipts

7/25/23 SFTL

Softline has confirmed the exchange of its shares for Noventiq receipts

7/24/23 SOFL

Obsky MCC will not pay mineral extraction tax

7/24/23 NVTK

Tambov Power Supply Company reported for 6 months of 2023

7/24/23 TASB

RusHydro in the first half decreased energy generation by 1.1%

7/24/23 HYDR

Mosgorlombard plans to go public in the fourth quarter of 2023

7/24/23 MGKL

Detsky Mir summed up interim results of the share buyback program

7/24/23 DSKY